# Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer

https://mdr.nims.go.jp/datasets/9020fc9e-7653-4a93-be23-2304e9db254e

## Download

- [Combinatorial treatment using bevacizumab pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer.pdf](https://mdr.nims.go.jp/filesets/97be40e5-dcbd-45c5-806e-83016075bebe/download)

## Id

9020fc9e-7653-4a93-be23-2304e9db254e

## Local identifier



## Visibility

open_to_public

## State

published

## Created at

2023-11-06T05:03:41.793033Z

## Updated at

2025-07-16T07:16:22.403841Z

## Published at

2023-11-09T04:30:15.135923Z

## Doi

https://doi.org/10.48505/nims.4315

## First published url

https://doi.org/10.1080/14686996.2023.2274819

## Date published

2023-12-31

## Recorded date published

2023-12-31

## Resource type

journal_article

## Manuscript type

accepted_manuscript

## Collection



## Title

- title: Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica
    nanoparticles for non-small cell lung cancer
  title_type: original
  lang: en

## Description

- description: Non-small cell lung cancer (NSCLC) is a life-threatening cancer associated
    with a higher mortality rate. Despite promising results shown by combination therapies,
    there remains a need for efficient drug delivery materials capable of combining
    various drugs, imaging agents, and targeting agents to enhance treatment efficacy.
    In this study, we present the synthesis of novel core-shell hollow mesoporous
    silica nanoparticles (@MSN) with bimodal porosity and a large surface area (694 m2/g)
    to facilitate targeted drug delivery for NSCLC treatment. The hollow core-shell
    structure enables the loading of a substantial quantity of the pemetrexed drug,
    up to 839 µg/mg, with a sustained release of 20% within 48 hours. The MSN is surface
    functionalised with amino and carboxyl groups to accommodate an imaging agent
    and facilitate the attachment of the targeting drug bevacizumab. These particles
    exhibit rapid uptake by both A549 and PC-9 cells. Moreover, the targeting by bevacizumab
    leads to higher cytotoxicity within 48 hours and induces apoptosis more effectively
    than the non-functionalised samples. As a versatile drug delivery platform, the
    hollow core-shell MSN demonstrated in this study holds great potential for various
    drug delivery applications.
  description_type: abstract
  lang: en

## Creator

- name: Deepika Radhakrishnan
  role: author
  orcid: https://orcid.org/0000-0002-6844-8499
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
- name: Vaishwik Patel
  role: author
  orcid: https://orcid.org/0000-0002-4561-4263
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
- name: Shan Mohanan
  role: author
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
- name: Sharon Wong
  role: author
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
- name: Jacob Netherton
  role: author
  organization: The University of Newcastle
  department: School of Biomedical Sciences and Pharmacy
- name: Ajay Karakoti
  role: author
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
- name: Ajayan Vinu
  role: author
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials

## Contact agent

- name: Ajayan Vinu
  email: Ajayan.Vinu@newcastle.edu.au
  orcid: https://orcid.org/
  organization: The University of Newcastle
  department: Global Innovative Center for Advanced Nanomaterials
  ror: https://ror.org/

## Publisher

organization: Taylor & Francis

## Managing organization



## Keyword

- subject: Non-small cell lung cancer (NSCLC)
  schema: not_defined
- subject: combinatorial treatment
  schema: not_defined
- subject: core-shell silica nanoparticles
  schema: not_defined

## Rights

- identifier: https://creativecommons.org/licenses/by-nc/4.0/

## Other identifier(s)



## Data origin

- data_origin_type: other

## Embargo



## Journal

- title: Science and Technology of Advanced Materials
  issn: '14686996'
  volume: '24'
  article_number: '2274819'

## Conference



## Related item



## Funding



## Instrument



## Instrument operator



## Instrument managing organization



## Measurement method



## Specimen



## Chemical composition



## Structure for specimen



## Structural feature for specimen



## Specific property for specimen



## Process for specimen treatment



## Computational method



## Energy level/transition state



## Software



## Custom property



## Fileset

- id: 97be40e5-dcbd-45c5-806e-83016075bebe
  filename: Combinatorial treatment using bevacizumab pemetrexed loaded core-shell
    silica nanoparticles for non-small cell lung cancer.pdf
  content_type: application/pdf
  size: 5337762
  md5: 8adf10252370837d1fa1d9df94217cb3

## Thumbnail

fileset_id: 97be40e5-dcbd-45c5-806e-83016075bebe
filename: Combinatorial treatment using bevacizumab pemetrexed loaded core-shell silica
  nanoparticles for non-small cell lung cancer.pdf